Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)

NCT01715636 is registered in ClinicalTrials.gov with Andrew Carr as lead sponsor.

NCT NCT01715636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)
Lead sponsor
Andrew Carr
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2012
Completion date
July 31, 2014
Enrollment
100 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv nonoccupational post-exposure prophylaxis in men who have sex with men